Top health care stocks were flat to lower in pre-market trading Friday.
Early movers include:
(-) Seelos Therapeutics (SEEL), which was plunging more than 20% as the company filed a prospectus supplement for a $16.5 million offering of common shares.
In other sector news:
(-) Alexion Pharmaceuticals (ALXN) was marginally lower after saying the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to extend the current marketing authorization of SOLIRIS (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive with a relapsing course of the disease.
(+) GlaxoSmithKline (GSK) was up 1% after it reported that results from its pivotal DREAMM-2 study of two doses of belantamab mafodotin for the treatment of multiple myeloma achieved its primary objective.
Price: 122.45, Change: -1.04, Percent Change: -0.84
|Consensus Estimates for Zynex's Q4, 2019, 2020 Years...|
|Alleghany's 2020, and Q1 Estimates Lowered but 2021 ...|
|Zscaler's 2021 Earnings Estimate Cut|
|Wynn Resorts' Consensus Forecasts for Q1, 2020, and ...|
|Cimarex Energy's 2020, 2021, and Q1 Earnings Estimat...|